Abstract 1684P
Background
Survival rates for cancer have improved steadily. Consequently, the late physical and psychological effects of treatment may negatively impact the well-being of cancer survivors. This study aimed to provide an overview of patients' lives after remission and their evolving perceptions.
Methods
In the absence of a validated questionnaire suitable to our study, we conducted a cross-sectional survey including 110 cancer survivors regardless of gender, age, and cancer site using a self-developed questionnaire designed to explore various aspects of survivors’ lives, including functional, social and emotional well-being.
Results
Median age was 58 years [37-81] and 75% of patients were women. Median follow up was 45 months [24-101]. Breast cancer was the most common cancer (44%), followed by colorectal (32.7%) and gynecologic (17.3%) cancers. All patients received chemotherapy, 33% had hormone therapy, 65.5% had radiotherapy and 96 % underwent surgery. Thirty-three patients (30%) reported ongoing fatigue and lack of energy, while 25.9% experienced cognitive decline. Persistent pain was reported by 40% of survivors. Those treated with oxaliplatin or taxane-based chemotherapy reported peripheral neuropathy in 38.4% of cases. Positive lifestyle changes were reported in 42 patients (38.9%), including adoption of healthier eating habits (40.9%), engaging in sports (31%), and an increased commitment to religious practices (14.3%). Sixty-one percent of patients resumed work, with 15.7% undergoing job reassignment. Sixty percent expressed greater appreciation for life post-cancer, and 70.9% felt their lives had acquired deeper meaning. Fear of cancer recurrence (FCR) was reported by 44 patients (40%), significantly more prevalent among females (61% vs 40%, p=0.038) and those under 50 years old (69% vs 42%, p=0.001). Sleep disturbances were reported by 41 patients (37.3%), significantly impacted by FCR (OR= 3.77 [1.12-7.87]) and pain (OR= 2.56 [1.08-5.87]).
Conclusions
Years after cancer, patients have to deal with changes concerning their physical and emotional well-being. Thus, treatment protocols should be well-considered and follow-up programs should target these disturbances timely.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1709P - Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Presenter: Deepak Kilari
Session: Poster session 11
1710P - Exposure-response (E/R) relationship of nivolumab (N) and ipilimumab (I) in patients (pts) with metastatic renal cell clear cell carcinoma (mRCC) from the randomised phase II BIONIKK study
Presenter: Benoit Blanchet
Session: Poster session 11
1711P - Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
Presenter: John McGrane
Session: Poster session 11
1712P - Real-world efficacy of first-line nivolumab plus ipilimumab and its practical predictive biomarkers in advanced renal cell carcinoma: First analysis from RENOIR study [KCSG GU22-13]
Presenter: Jwa Hoon Kim
Session: Poster session 11
1713P - A deep learning approach utilizing the electronic health record (EHR) to identify cancer recurrence in renal cell carcinoma (RCC)
Presenter: Jue Hou
Session: Poster session 11
1714P - Detection and monitoring of translocation renal cell carcinoma via epigenomic profiling of cell-free DNA
Presenter: Simon Garinet
Session: Poster session 11
1715P - Interim analysis results from a phase II study of adjuvant penpulimab in very high-risk clear cell renal cell carcinoma
Presenter: Xu Zhang
Session: Poster session 11
1716P - Primary resistance to front-line immune-based combinations in patients with advanced renal cell carcinoma (ARON-1)
Presenter: martina catalano
Session: Poster session 11